Patent application number | Description | Published |
20090137780 | METHOD FOR PRODUCTION OF PEPTIDE THIOESTER COMPOUND - The present invention provides a process for producing a peptide thioester compound, characterized by comprising: (A) forming a peptide by a solid-phase synthesis method using a resin modified with a linker represented by the formula (1) as a solid phase; (B) cleaving a bond between the solid phase and the peptide with at least one acid selected from dilute hydrochloric acid, dilute sulfuric acid, formic acid, and acetic acid to produce a peptide having a carboxyl group at the C-terminus; and (C) reacting a thiol compound with the peptide at −100 to 0° C. in the presence of a condensing agent in a solvent: (1) wherein R | 05-28-2009 |
20100080794 | MUTANT POLYPEPTIDE HAVING EFFECTOR FUNCTION - Mutant polypeptides of the present invention contain an Fc region in which a cysteine residue is substituted for the second amino acid from the glycosylation site to the N terminal side in the Fc region. The Fc region is preferably a human IgG Fc region. The mutant polypeptides of the present invention may also contain an N-linked sugar chain at the glycosylation site in Fc region. Furthermore, a polypeptide domain other than the Fc region of the mutant polypeptides of the present invention may be a polypeptide molecule that recognizes a human cell surface molecule. | 04-01-2010 |
20100306864 | POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION - Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function. | 12-02-2010 |
20110172392 | METHOD FOR PRODUCING PEPTIDE - The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an —SMe group; (b) allowing the —SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b). | 07-14-2011 |
20110313136 | IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME - A full-length IgG-Fc fragment having a substantially homogeneous sugar chain added thereto, and a process for producing the full-length IgG-Fc fragment. Specifically, an IgG-Fc fragment has a sugar chain added thereto, in which the sugar chain is added to the same position as that in a naturally occurring IgG-Fc fragment, any one amino acid residue selected from 1st to 30th amino acid residues from the sugar chain-added amino acid residue on the N-terminal side of the sugar chain-added amino acid residue is substituted by a Cys residue and at least one Met reside is substituted by an amino acid reside other than a Met residue. | 12-22-2011 |
20120047586 | POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION - Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function. | 02-23-2012 |
20120114595 | SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME - Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position corresponding to the 69-position of the amino acid sequence of human AILIM extracellular domain, said amino acid sequence being depicted in SEQ ID NO: 7, and no sugar chain is added at positions corresponding to the 3-position and the 90-position of the amino acid sequence. | 05-10-2012 |
20140315800 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide - [Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analogue thereof being replaced by glycosylated amino acids. | 10-23-2014 |
20140336116 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide - [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid. | 11-13-2014 |
20140369964 | GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon β activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon β activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments. | 12-18-2014 |